• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

从一名有印度旅行史的美国中西部医院患者中分离出的耐碳青霉烯类细菌：治疗策略与临床结果

Carbapenem-Resistant Isolated From a Patient in a Midwestern U.S. Hospital With a History of Indian Travel: Therapeutic Strategies and Clinical Outcomes.

作者信息

Phan Christopher, Tsai Kristen, Gill Christian M, Chamberland Robin, Hendrix Christian, Hou Rong

机构信息

Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, Missouri 63110, USA.

SSM Health Saint Louis University Hospital, St. Louis, Missouri 63110, USA.

出版信息

Case Rep Infect Dis. 2025 Jan 31;2025:8155592. doi: 10.1155/crdi/8155592. eCollection 2025.

DOI:10.1155/crdi/8155592
PMID:39949481
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11824306/
Abstract

Carbapenemases have had increasing prevalence within the United States and worldwide. Here, we present a case of carbapenem-resistant (CRKP) which is unique due to the rarity of multiple mechanisms of resistance within the harboring New Delhi metallo--lactamases (NDM), oxacillinase-48 (OXA-48)-like, and cefotaximase (CTX-M) resistance genes, detected in a patient following an international travel. This case demonstrates the need for a multidisciplinary approach to optimize the treatment of multidrug-resistant Gram-negative organisms.

摘要

碳青霉烯酶在美国及全球范围内的流行率都在不断上升。在此，我们报告一例耐碳青霉烯类肺炎克雷伯菌（CRKP）病例，该病例具有独特性，因为在一名有国际旅行史的患者中检测到了携带新德里金属β-内酰胺酶（NDM）、类氧头孢烯酶-48（OXA-48）和头孢噻肟酶（CTX-M）耐药基因的多种耐药机制，实属罕见。该病例表明需要采用多学科方法来优化对多重耐药革兰氏阴性菌的治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54f2/11824306/15278c95e510/CRIID2025-8155592.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54f2/11824306/3f937554f90e/CRIID2025-8155592.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54f2/11824306/15278c95e510/CRIID2025-8155592.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54f2/11824306/3f937554f90e/CRIID2025-8155592.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54f2/11824306/15278c95e510/CRIID2025-8155592.002.jpg

相似文献

1
Carbapenem-Resistant Isolated From a Patient in a Midwestern U.S. Hospital With a History of Indian Travel: Therapeutic Strategies and Clinical Outcomes.从一名有印度旅行史的美国中西部医院患者中分离出的耐碳青霉烯类细菌：治疗策略与临床结果
Case Rep Infect Dis. 2025 Jan 31;2025:8155592. doi: 10.1155/crdi/8155592. eCollection 2025.
2
Multicenter Genomic Analysis of Carbapenem-Resistant Klebsiella pneumoniae from Bacteremia in China.中国血流感染碳青霉烯类耐药肺炎克雷伯菌的多中心基因组分析。
Microbiol Spectr. 2022 Apr 27;10(2):e0229021. doi: 10.1128/spectrum.02290-21. Epub 2022 Mar 1.
3
Carbapenem-resistant hypermucoviscous clinical isolates from a tertiary hospital in China: Antimicrobial susceptibility, resistance phenotype, epidemiological characteristics, microbial virulence, and risk factors.中国一家三级医院耐碳青霉烯类超黏液型临床分离株：抗菌药物敏感性、耐药表型、流行病学特征、微生物毒力和危险因素。
Front Cell Infect Microbiol. 2022 Dec 21;12:1083009. doi: 10.3389/fcimb.2022.1083009. eCollection 2022.
4
Novel Carbapenem-Resistant ST147 Coharboring , and Extended-Spectrum β-Lactamases from Pakistan.来自巴基斯坦的携带新型碳青霉烯耐药性、超广谱β-内酰胺酶的ST147菌株
Infect Drug Resist. 2020 Jul 2;13:2105-2115. doi: 10.2147/IDR.S251532. eCollection 2020.
5
Clinical and Genomic Characterization of Carbapenem-Resistant with Concurrent Production of NDM and OXA-48-like Carbapenemases in Southern California, 2016-2022.2016 - 2022年南加州同时产NDM和OXA - 48样碳青霉烯酶的耐碳青霉烯菌的临床和基因组特征
Microorganisms. 2023 Jun 30;11(7):1717. doi: 10.3390/microorganisms11071717.
6
Genomic analysis of carbapenemase-encoding plasmids and antibiotic resistance in carbapenem-resistant isolates from Vietnam, 2021.2021年越南耐碳青霉烯类分离株中碳青霉烯酶编码质粒的基因组分析及抗生素耐药性
Microbiol Spectr. 2025 Apr 15;13(5):e0311524. doi: 10.1128/spectrum.03115-24.
7
A pentaplex real-time PCR assay for rapid identification of major beta-lactamase genes KPC, NDM, CTX, CMY, and OXA-48 directly from bacteria in blood.一种五重实时 PCR 检测方法，可直接从血液中的细菌中快速鉴定主要的β-内酰胺酶基因 KPC、NDM、CTX、CMY 和 OXA-48。
J Med Microbiol. 2021 Dec;70(12). doi: 10.1099/jmm.0.001465.
8
High prevalence of OXA-48-like and NDM carbapenemases among carbapenem resistant of clinical origin from Iran.来自伊朗临床分离的耐碳青霉烯类细菌中，OXA-48样和NDM碳青霉烯酶的高流行率。
Iran J Microbiol. 2023 Oct;15(5):609-615. doi: 10.18502/ijm.v15i5.13866.
9
Co-production of NDM-1 and OXA-232 by ST16 Klebsiella pneumoniae, Italy, 2016.2016年，意大利，ST16型肺炎克雷伯菌同时产生NDM-1和OXA-232。
Future Microbiol. 2017 Oct;12:1119-1122. doi: 10.2217/fmb-2017-0041. Epub 2017 Sep 6.
10
OXA-181-Like Carbapenemases in Klebsiella pneumoniae ST14, ST15, ST23, ST48, and ST231 from Septicemic Neonates: Coexistence with NDM-5, Resistome, Transmissibility, and Genome Diversity.肺炎克雷伯菌 ST14、ST15、ST23、ST48 和 ST231 中的 OXA-181 类碳青霉烯酶：与 NDM-5、耐药组、传播性和基因组多样性共存于败血症新生儿中。
mSphere. 2021 Jan 13;6(1):e01156-20. doi: 10.1128/mSphere.01156-20.

引用本文的文献

1
Molecular characteristics and antimicrobial susceptibility of carbapenem-resistant in a multicenter study in Ningbo, China.中国宁波一项多中心研究中耐碳青霉烯类细菌的分子特征及抗菌药敏情况
Front Microbiol. 2025 Jul 21;16:1628592. doi: 10.3389/fmicb.2025.1628592. eCollection 2025.

本文引用的文献

1
Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.美国传染病学会2023年抗微生物药物耐药革兰氏阴性菌感染治疗指南
Clin Infect Dis. 2023 Jul 18. doi: 10.1093/cid/ciad428.
2
Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults.健康成年人中头孢他啶-阿维巴坦（COMBINE）联合氨曲南的药代动力学：一项 1 期、开放标签研究。
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0093622. doi: 10.1128/aac.00936-22. Epub 2022 Nov 17.
3
Safety of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers.
一项在健康成年志愿者中开展的 I 期、开放性标签研究评估头孢他啶-阿维巴坦与氨曲南联用的安全性（COMBINE）。
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0093522. doi: 10.1128/aac.00935-22. Epub 2022 Nov 17.
4
Prevalence of carbapenemase genes among carbapenem-nonsusceptible collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents.五年期间在美国医院收集的碳青霉烯不敏感菌中碳青霉烯酶基因的流行情况以及头孢他啶/阿维巴坦和对照药物的活性。
JAC Antimicrob Resist. 2022 Sep 30;4(5):dlac098. doi: 10.1093/jacamr/dlac098. eCollection 2022 Oct.
5
Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies.头孢地尔在 CREDIBLE-CR 和 APEKS-NP 三期随机研究中治疗产金属β-内酰胺酶病原体感染。
Clin Infect Dis. 2022 Sep 29;75(6):1081-1084. doi: 10.1093/cid/ciac078.
6
Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019.2014 年至 2019 年连续五年跨国 SIDERO-WT 监测研究中革兰氏阴性病原体对头孢地尔的敏感性。
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0199021. doi: 10.1128/AAC.01990-21. Epub 2021 Nov 22.
7
Assessing the in vitro impact of ceftazidime on aztreonam/avibactam susceptibility testing for highly resistant MBL-producing Enterobacterales.评估头孢他啶对产超广谱β-内酰胺酶肠杆菌科高度耐药菌株中阿维巴坦/头孢他啶药敏试验的体外影响。
J Antimicrob Chemother. 2021 Mar 12;76(4):979-983. doi: 10.1093/jac/dkaa531.
8
Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014).全球监测项目（SIDERO-WT-2014）中临床分离株对头孢他啶的亲和力降低机制（铁载体头孢菌素）。
J Glob Antimicrob Resist. 2020 Sep;22:738-741. doi: 10.1016/j.jgar.2020.07.009. Epub 2020 Jul 21.
9
Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model.采用中空纤维感染模型测定新型头孢他啶/阿维巴坦联合氨曲南治疗产 NDM-1 肠杆菌科的最佳剂量。
J Antimicrob Chemother. 2020 Sep 1;75(9):2622-2632. doi: 10.1093/jac/dkaa197.
10
Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales.头孢他啶-阿维巴坦联合氨曲南治疗产金属β-内酰胺酶肠杆菌科血流感染的疗效。
Clin Infect Dis. 2021 Jun 1;72(11):1871-1878. doi: 10.1093/cid/ciaa586.